Novartis Invests In Start-up Sideris | Chemical & Engineering News
Volume 91 Issue 43 | p. 17 | Concentrates
Issue Date: October 28, 2013

Novartis Invests In Start-up Sideris

Department: Business
Keywords: venture capital, transfusional iron overload

Novartis has signed a pact giving it the exclusive right to acquire Sideris Pharmaceuticals, a University of Florida spin-off, for up to $300 million. The deal is a companion to a $32 million fund-raising round for the biotech firm that was led by the venture capital company MPM Capital. Based in Boston and Gainesville, Fla., Sideris has developed SP-420, a small molecule that selectively binds iron and removes it from the body. It is intended to treat iron overload caused by multiple transfusions.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment